Dr Maxwell on Strategies to Optimize Genetic Testing in Metastatic Prostate Cancer
Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.
Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.
In this EMA/EORTC workshop, CMF reported its observations and preliminary solutions to address treatment optimisation
Patients with siNETs metastatic to both the liver and peritoneum have favorable outcomes after aggressive surgical cytoreduction, with the best outcomes observed after complete cytoreduction.…
Pembrolizumab monotherapy showed antitumour activity and manageable toxicity in patients with BCG-unresponsive high-risk Ta or T1 bladder cancer without carcinoma in situ and could potentially…
Onyeanunam Ekeke, MBBS, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria, discusses the rising rates of prostate cancer in African men. In sub-Saharan Africa,…
Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.
For patients with polycythemia vera, rusfertide treatment reduces the use of phlebotomy and maintains hematocrit of less than 45 percent.
This clinical care review summarizes government policies for the safe conduct of clinical trials using the telehealth and decentralized clinical trials digital health models.
The FDA has approved ColoSense for use as a screening test in adults 45 years of age or older who are at average risk of…
An abstract is unavailable.
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.